Australia's Nexsen jumps on US market entry plans
06/11/2025 02:45
** Shares of Nexsen Limited NXN.AX rise as much as 20.6% to A$0.205; set for strongest trading session ever, if current trend holds ** Nano biotech firm appoints MCRA, a multi-service, integrated business advising co to accelerate its U.S. market entry for its GBS Rapid Sensor and Kidney Function Diagnostics ** MCRA to also advise co on its U.S. FDA regulatory pathway ** Stock down 31.6% since trading debut on October 14, including the day's moves (Reporting by Aamir Shaik Khalid in Bengaluru) ((aamir.sheikkhalid@thomsonreuters.com))
Recent news on Nexsen
See all newsBrief: Nexsen Appoints Professor Shekhar Kumta As Executive Director
Brief: Nexsen Entered Into Non-Binding Term Sheet With Flashdx Shenzhen To Establish JV
Brief: Nexsen Requests Trading Halt
Brief: Nexsen Secures First Hospital Partner In Asia
Australia's Nexsen surges on collaboration with Malaysia's IHH unit